Señales en vivo de CVAC | Maximiza tus Ganancias con Getagraph.com

COMPRAR 112305 min ago

@ $3.41

Emitido: 14 feb 2024 @ 15:58

Retorno: -18.65%

Señal anterior: feb 14 - 09:30

Señal anterior: Vender

Retorno: -2.14 %

Live Chart Being Loaded With Signals

Commentary (2 may 2024 @ 16:00):

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA)...

Stats
Volumen de hoy	406 813
Volumen promedio	800 283
Capitalización de mercado	620.16M
EPS	$-0.240 ( 2023-11-14 )
Próxima fecha de ganancias	( $-0.140 ) 2024-06-04
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.20
ATR14	$0.00400 (0.14%)

Volumen Correlación

Largo: 0.46 (neutral)

Corto: 0.36 (neutral)

Signal:(61.683) Neutral

CureVac AG Correlación

10 Correlaciones Más Positivas
BELFA	0.934
CVLT	0.929
BELFB	0.926
SPNS	0.922
EWZS	0.911
XP	0.91
PTC	0.91
GLDD	0.907
XOG	0.904
CSGP	0.903

10 Correlaciones Más Negativas
PAYS	-0.885
OBNK	-0.883
DTEA	-0.882
CIDM	-0.869
TRMD	-0.866
PLXP	-0.862
AY	-0.847
NLSP	-0.847
EDRY	-0.845
JRSH	-0.844

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

CureVac AG Correlación - Moneda/Commodity

0.50
( weak )

0.41
( neutral )

0.00
( neutral )

0.66
( moderate )

0.15
( neutral )

CureVac AG Finanzas

Annual	2023
Ingresos:	$52.66M
Beneficio Bruto:	$-91.08M (-172.97 %)
EPS:	$-1.150

FY	2023
Ingresos:	$52.66M
Beneficio Bruto:	$-91.08M (-172.97 %)
EPS:	$-1.150

FY	2022
Ingresos:	$67.42M
Beneficio Bruto:	$-116.57M (-172.91 %)
EPS:	$-1.320

FY	2021
Ingresos:	$102.99M
Beneficio Bruto:	$-135.21M (-131.28 %)
EPS:	$-2.28

Financial Reports:

No articles found.

CureVac AG

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.